PITTSBURGH, December, 2013 — Gateway Analytical will present a scientific poster discussing the application of Raman Chemical Imaging for testing particles in inhalable pharmaceuticals at this month’s Drug Delivery to the Lungs 24 (DDL 24) Conference on December 12, 2013. This annual meeting serves as Europe’s premier conference dedicated to pulmonary and nasal drug delivery and serves as an opportunity to learn the latest research and technologies being used and network with peers as well as other professionals from the pharmaceutical industry.
Oksana Olkhovyk, PhD will be presented to discuss Raman-based Analysis of Dispersed versus Aggregated Drug Particles in MDI Formulations for Chemically-Specific Sizing and Polymorphic Purity Assessment, and will discuss the results of using Raman Chemical Imaging (RCI) to investigate the Active Pharmaceutical Ingredients (API) particle size distribution (PSD) and degree of drug particle aggregation in a commercial MDI. Dr Olkhovyk will discuss the benefits of using Raman Chemical Imaging as a powerful analytical tool for differentiating particles by their chemical make-up to provide means to evaluate degree of drug-specific aggregates, which is especially effective in analysis of combination inhalation products.
In addition to the scientific poster presentation at the conference, Gateway Analytical will host a VIP event at the Scotch Whisky Experience to meet with DDL 24 attendees and further discuss the company’s experience in advanced analytical testing services for a wide range of pharmaceutical drug product types. During this cocktail reception, guests will be treated to an interactive tour of the distillery and tastings of authentic Scotch Malt Whisky.
“We are very excited to display our data at the DDL24 conference and present our findings to the pharmaceutical scientists and attendees at this conference,” said Dr Olkhovyk, Senior Scientist at Gateway Analytical. “Our data discusses the benefits of using Raman Chemical Imaging (RCI) for chemically-specific testing – which is extremely important in the development of inhalation drugs.”
RCI analysis aids in understanding dispersion of the drug particles and inhalation product aerosolization performance without time-consuming impaction analysis testing. With the recent release of the FDA Draft Guidance on Fluticasone Propionate and Salmeterol Xinafoate, our services can help to guide pharmaceutical customers through touch regulatory waters as they develop these types of DPI products and establish their bioequivalence.”
Gateway Analytical is a full service FDA registered and inspected laboratory with specialized expertise in state-of-the-art techniques for chemically specific particle sizing and particulate contamination identification. The lab’s accreditations include cGMP-compliant, ISO 9001:2008, 21 CFR parts 210 & 211, 21 CFR part 820, and ICH Q7. By utilizing techniques such as optical and polarized light microscopy, Raman and FTIR spectroscopy, SEM/EDS and Raman, visible fluorescence and NIR chemical imaging, Gateway Analytical’s scientists are able to offer unique forensic-based-testing methods to quickly address pharmaceutical issues such as identifying when and where foreign particulate matter enter a manufacturing process, pinpointing the root cause of product failures or investigating the source of product stains or discoloration.
For more information on Gateway Analytical’s pharmaceutical forensic and investigation services, contact Tracey Safran, Senior Account Manager, at email@example.com.
About Gateway Analytical
Based in Gibsonia, Pa., Gateway Analytical, LLC partners with companies in need of high-quality laboratory analysis that do not have the time, resources or capabilities for specialized, comprehensive testing. Through conventional and innovative testing methods, the company provides expert laboratory services and analytical solutions for the pharmaceutical, forensic and materials science industries.
Gateway Analytical is a subsidiary of ChemImage Corporation, a leader in chemical imaging technology and instrumentation.
ChemImage Corporation, a leader in hyperspectral and Raman chemical imaging technology provides innovative instrumentation, analysis software, contract services and expert consulting to government, industrial and academic organizations. The company’s proprietary, state-of-the-art imaging technology has many applications, including defense, security, pharmaceuticals, forensics and biomedical diagnostic research, which can reveal critical chemical and biological information from a variety of material systems.
ChemImage’s headquarters are located in Pittsburgh, PA, where it pioneers research and development, as well as providing engineering and manufacturing which develops innovative products for the global marketplace.